VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Monday, December 29, 2025
Stock Comparison
Unicharm Corporation vs Bristol-Myers Squibb Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Unicharm Corporation
8113 · Tokyo Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Unicharm Corporation's moat claims, evidence, and risks.
View 8113 analysisBristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisComparison highlights
- Moat score gap: Unicharm Corporation leads (60 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Unicharm Corporation has 5 segments; Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)).
- Moat breadth: Unicharm Corporation has 7 moat types across 3 domains; Bristol-Myers Squibb Company has 4 across 3.
Primary market context
Unicharm Corporation
Baby and Child Care Products
Disposable baby diapers and baby wipes
Japan, Asia, Middle East, and selected other markets
Consumers (parents/caregivers)
Branded manufacturer
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Side-by-side metrics
Moat coverage
Shared moat types
Unicharm Corporation strengths
Bristol-Myers Squibb Company strengths
Segment mix
Unicharm Corporation segments
Full profile >Baby and Child Care Products
Oligopoly
Feminine Care Products
Oligopoly
Wellness Care Products (Adult Incontinence)
Oligopoly
Pet Care Products
Competitive
Industrial Materials and Other Businesses
Competitive
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.